Multicenter Study on Fibrotic Valvular Heart Disease in Patients With Parkinson's Disease Treated With Dopamine Agonists
Launched by GERMAN PARKINSON STUDY GROUP (GPS) · Sep 12, 2005
Trial Information
Current as of May 21, 2025
Unknown status
Keywords
ClinConnect Summary
Rare incidence of pleuropulmonary and retroperitoneal fibrosis are known complications during the long-time therapy of Parkinson's disease (PD) with ergot-drug derivatives including some ergot dopamine agonists. Particularly the appearance of fibrotic valvular heart disease of Parkinson patients under Pergolide therapy caused an intense discussion about the safety of dopamine agonists at all. Single case reports of similar heart valve changes under the therapy of Bromocriptin and probably Cabergoline pointed to an effect of the whole substance class of the ergot-dopamine agonists.
Cross-Se...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \> 18 years
- • Diagnosis of Morbus Parkinson
- • Written informed consent
- Exclusion Criteria:
- • Patients with a history of carcinoid syndrome
- • Patients with a history of post-inflammatory (rheumatic), degenerative (calcified) or ischaemic coronary heart or valvular heart disease
- • Previous medication with ergot-derived drugs (eg. Methysergide, Ergotamine) except dopamine receptor agonists or anorectic drugs (eg. Fenfluramine, Dexfenfluramine)
About German Parkinson Study Group (Gps)
The German Parkinson Study Group (GPS) is a collaborative network dedicated to advancing research and treatment options for Parkinson's disease. Comprising leading neurologists, researchers, and healthcare professionals from various institutions across Germany, GPS aims to facilitate high-quality clinical trials and observational studies. By fostering interdisciplinary collaboration, the group seeks to enhance our understanding of Parkinson's disease, improve patient outcomes, and promote innovative therapeutic strategies. With a commitment to excellence in research and patient care, GPS plays a pivotal role in the global effort to combat this complex neurodegenerative disorder.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Marburg, Hessen, Germany
Patients applied
Trial Officials
Wolfgang Oertel, Prof. Dr.
Study Chair
Universitätsklinikum Marburg und Gießen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials